A new number 1 drug? Keytruda tapped to top the 10 biggest blockbusters on the world stage by 2024
Analysts may be fretting about Keytruda’s longterm prospects as a host of rival therapies elbow their way to the market. But the folks at Evaluate Pharma are confident that last year’s $7 billion earner is headed for glory, tapping it to beat out the current #1 therapy Humira as AbbVie watches that franchise swoon over the next 5 years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.